LumiraDx Limited (LMDXF)

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-338.04	-447.79	-100.93	-240.98	-132.81	-115.15
Depreciation & Amortization	32.68	33.29	25.7	10.91	8	5.52
Asset Writedown & Restructuring Costs	49.44	49.44	-	-	-	1.18
Stock-Based Compensation	27.76	35.21	33.91	3.19	3.97	3.96
Other Operating Activities	72.56	158.96	-14.52	144.43	17.75	22.28
Change in Accounts Receivable	25.59	53.32	-2.32	-95.53	6.39	1.77
Change in Inventory	35.92	-2.27	-66.87	-73.3	-8.39	-0.21
Change in Accounts Payable	-35.61	-42.27	-9.54	101.95	13.34	1.2
Operating Cash Flow	-129.71	-162.11	-134.58	-149.33	-91.76	-79.46
Capital Expenditures	-10.81	-24.98	-106.35	-64.38	-10.63	-8.44
Cash Acquisitions	-	-	-	-	-0.58	-4.36
Sale (Purchase) of Intangibles	-	-	-	-	-0.1	-
Investing Cash Flow	-10.81	-24.98	-106.35	-64.38	-11.31	-12.8
Long-Term Debt Issued	-	95.51	361.83	133.31	127.7	37.87
Long-Term Debt Repaid	-	-7.67	-145.98	-43.45	-51.19	-3.18
Net Debt Issued (Repaid)	-8.52	87.84	215.85	89.86	76.51	34.69
Issuance of Common Stock	100.32	104.06	38.67	0.04	-	-
Repurchase of Common Stock	-	-	-	-	-2.04	-
Other Financing Activities	-33.66	-26.61	-35.5	-15.71	-3.77	-9.01
Financing Cash Flow	58.14	165.29	219.02	236.59	70.7	250.82
Foreign Exchange Rate Adjustments	1.28	-10.33	-7.12	-1.09	0.48	-0.43
Net Cash Flow	-81.11	-32.14	-29.03	21.79	-31.89	158.14
Free Cash Flow	-140.52	-187.09	-240.93	-213.71	-102.38	-87.89
Free Cash Flow Margin	-111.07%	-73.52%	-57.17%	-153.58%	-442.40%	-346.22%
Free Cash Flow Per Share	-0.45	-0.66	-1.48	-1.62	-0.78	-1.06
Levered Free Cash Flow	-54.01	-50.28	-250.46	-223.22	-92.79	-
Unlevered Free Cash Flow	-23.35	-23.15	-192.61	-188.74	-68.55	-
Change in Net Working Capital	-56.48	-71.93	77.62	75.51	-2.1	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.